Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s
Antiviral Therapy · 2017-02 · 22 (2) · 113-126
DOI: 10.3851/imp3093 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Antiviral Therapy, online erschienen am 01.02.2016. Verfasst von Theodoros Kelesidis und 9 weiteren Autor:innen. Beteiligte Einrichtung: David Geffen School of Medicine at University of California - Los Angeles, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Carotid Intima-Media Thickness. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Background
The role of oxidized lipoproteins (high-density [HDLox] and low-density [LDLox]) and total lipoprotein particle (Lp) number and size in HIV-related cardiovascular disease (CVD) is unclear. The goal of this study was to evaluate changes of these biomarkers and their associations with rate of carotid intima media thickness progression over 3 years (ΔCIMT) in chronic HIV infection.
Methods
Prospective study of 234 HIV-infected anti-retroviral treatment-naive participants without CVD who were randomized to receive tenofovir-emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir or raltegravir (RAL) and achieved plasma HIV-1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- David Geffen School of Medicine at University of California - Los Angeles, Los Angeles, CA, USA.
- Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
- Case Western Reserve University School of Medicine, Cleveland, OH, USA.
- University Hospitals Case Medical Center, Cleveland, OH, USA.
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Kelesidis, T., Tran, T. T. T., Brown, T. T., Moser, C., Ribaudo, H. J., Dube, M. P., Yang, O. O., McComsey, G. A., Stein, J. H., & Currier, J. S. (2017). Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s. Antiviral Therapy, 22(2), 113-126. https://doi.org/10.3851/imp3093
Vancouver
Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dube MP, et al. Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s. Antiviral Therapy. 2017;22(2):113-126. doi:10.3851/imp3093
BibTeX
@article{Kelesidis2017,
author = {Kelesidis, Theodoros and Tran, Thuy Tien T and Brown, Todd T and Moser, Carlee and Ribaudo, Heather J and Dube, Michael P and Yang, Otto O and McComsey, Grace A and Stein, James H and Currier, Judith S},
title = {Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s},
journal = {Antiviral Therapy},
year = {2017},
volume = {22},
number = {2},
pages = {113--126},
doi = {10.3851/imp3093}
}
EUVIMED